Pascal Biosciences
  • Home
  • Company
    • About
    • Leadership
    • Board of Directors
  • Programs
    • Overview
    • Cannabinoid therapeutic for treating COVID-19
    • PAS-403 for Glioblastoma
    • PAS-393 for Cancer
    • Research: Pre-BCR antibody for Leukemia
  • News
  • Investors
  • Contact
  • AGM December 18, 2020
Skip to content

23Sep 2019

Pascal Biosciences Discovers Cannabinoids Activate the Major Histocompatibility Complex to Aid Cancer Treatment

  • Sep 23, 2019
  • Uncategorized

VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, Sept 23, 2019 –Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”) today revealed the mechanism whereby cannabinoids may directly aid in cancer treatment. Specific cannabinoids identified by Pascal scientists enhance the immunogenicity of tumor…

Read More

11Sep 2019

Pascal Biosciences to Present at International Cannabinoid Derived Pharmaceuticals Summit

  • Sep 11, 2019
  • Press Releases

VANCOUVER, BRITISH COLUMBIA, and SEATTLE, WASHINGTON, Sept 11, 2019 –Pascal Biosciences Inc. (TSX.V:PAS) (“Pascal” or the “Company”). Pascal announces that Dr. Patrick Gray, CEO, will present an update today on the Company’s lead cannabinoid-based drug candidate, PAS-403, at the Second…

Read More

Recent Posts

  • Pascal Amends Warrant Terms of Non-brokered Private Placement
  • Pascal Biosciences to Present at Cannabinoid Derived Pharmaceuticals Industry Review Summit
  • Pascal Amends Terms of Non-brokered Private Placement
  • Pascal Biosciences and SōRSE Technology Optimize Cannabinoid Formulation for Clinical Development of Cancer Treatment
  • Pascal Biosciences Appoints Mark van der Horst as Vice President of Corporate Communications

Categories

  • In the News
  • Press Releases
  • Uncategorized

Archives

  • January 2021
  • December 2020
  • November 2020
  • September 2020
  • August 2020
  • July 2020
  • May 2020
  • March 2020
  • October 2019
  • September 2019
  • May 2019
  • April 2019
  • March 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • July 2018
  • June 2018
  • February 2018
  • December 2017
  • September 2017
  • May 2017
  • March 2017
  • November 2016
  • October 2016
  • September 2016

About

Pascal Biosciences Inc. (TSX-V: PAS, FSE:6PB.F) is a biotechnology company focused on developing cannabinoid-based and targeted therapeutics to fight cancer.

Locations

USA

Fluke Hall, Suite 304
Box 352141
4000 Mason Road
Seattle, WA 98195-2141

Canada

280 7th Avenue East
Vancouver, BC V5T 0B4

Contact

Phone

206.221.3443

Email

info@pascalbiosciences.com

Investors

invest@pascalbiosciences.com

Partnering & Business Development

bd@pascalbiosciences.com

Let's Connect

  • Facebook
  • Twitter
  • Linked
  • Home
  • Company
  • Programs
  • News
  • Investors
  • Contact
  • Disclaimer
  • Legal Notices

© Copyright 2021 Pascal Biosciences Inc. All rights reserved.   Seattle Website Design by Jordan Crown Design

  • Home
  • Company
    • About
    • Leadership
    • Board of Directors
  • Programs
    • Overview
    • Cannabinoid therapeutic for treating COVID-19
    • PAS-403 for Glioblastoma
    • PAS-393 for Cancer
    • Research: Pre-BCR antibody for Leukemia
  • News
  • Investors
  • Contact
  • AGM December 18, 2020

‹ › ×